Mezigdomide is under clinical development by Bristol-Myers Squibb and currently in Phase III for Refractory Multiple Myeloma. According to GlobalData, Phase III drugs for Refractory Multiple Myeloma have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Mezigdomide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Mezigdomide (CC-92480) is under development for the treatment of newly diagnosed multiple myeloma, relapsed and/or refractory multiple myeloma (RRMM). The drug candidate is administered by oral route as a capsule and a next-generation CELMoD compound (cereblon E3 ligase modulation drugs) and acts by targeting cereblon protein.
Bristol-Myers Squibb overview
Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects. The company offers its products across the world to wholesalers, retail pharmacies, hospitals, medical professionals and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in New York City, New York, the US.
For a complete picture of Mezigdomide’s drug-specific PTSR and LoA scores, buy the report here.